



## PYROGENESIS CANADA INC.

### MANAGEMENT'S DISCUSSION AND ANALYSIS

This management's discussion and analysis ("MD&A") is intended to assist readers in understanding the business environment, strategies, performance and risk factors of PyroGenesis Canada Inc. ("PyroGenesis", or the "Company"). The MD&A provides the reader with a view and analysis, from the perspective of management, of the Company's financial results for the fourth quarter and the Fiscal year ended December 31, 2016. The MD&A has been prepared in accordance with National Instrument 51-102, Continuous Disclosure Requirements, and should be read in conjunction with the audited financial statements and related notes thereto of the Company for the year ended December 31, 2016.

The consolidated financial statements and MD&A have been reviewed by PyroGenesis' Audit Committee and were approved by its Board of Directors on April 28, 2017. The Board of Directors is responsible for ensuring that the Company fulfills its responsibilities for financial reporting and is ultimately responsible for reviewing and approving the MD&A. The Board of Directors carries out this responsibility principally through its Audit Committee. The Audit Committee is appointed by the Board of Directors and is comprised of independent directors. The Audit Committee reports its findings to the Board of Directors for its consideration when it approves the MD&A and financial statements for issuance to shareholders.

The following information takes into account all material events that took place up until April 28, 2017, the date on which the Company's Board of Directors approved this MD&A. Unless otherwise indicated, all amounts are presented in Canadian dollars. The Company's functional and reporting currency is the Canadian dollar.

Additional information regarding PyroGenesis is available on SEDAR ([www.sedar.com](http://www.sedar.com)), OTC Markets ([www.otcmarkets.com](http://www.otcmarkets.com)) and on the Company's website at [www.pyrogenesis.com](http://www.pyrogenesis.com).

### FORWARD-LOOKING STATEMENTS

This MD&A contains forward-looking statements. All statements other than statements of historical fact contained in this MD&A are forward-looking statements, including, without limitation, the Company's statements regarding its products and services; relations with suppliers and clients; future financial position; business strategies; potential acquisitions; potential business partnering; litigation; and plans and objectives. In certain cases, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" and similar words or the negative thereof. Although management of the Company believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

In particular, this MD&A contains forward-looking statements that relate, but are not limited, to:

- the Company's business strategies, strategic objectives and growth strategy;
- the Company's current and future capital resources and the need for additional financing;
- the Company's ability to increase sales, including the results of the successful completion of the Company's current projects;



- management's expectation that the Company will achieve sustained annual growth and profitability, and that gross margins will increase resulting in a decrease in cost of sales as a percentage of revenue; and
- the Company's overall financial performance.

By their nature, forward-looking statements require assumptions and are subject to inherent risks and uncertainties including those discussed herein. In particular, forward-looking statements relating to future sales, growth and profitability are based on the assumption that current projects will be completed and the Company will be awarded certain anticipated contracts pursuant to recent negotiations with, and statements made by, third parties. There is significant risk that predictions and other forward-looking statements will not prove to be accurate. Readers are cautioned to not place undue reliance on forward-looking statements made herein because a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed in the forward-looking statements.

The future outcomes that relate to forward-looking statements may be influenced by many factors, including, but not limited to, the strength of the Canadian, US and Asian economies; operational, funding, and liquidity risks; unforeseen engineering and environmental problems; delays or inability to obtain required financing and/or anticipated contracts; risks associated with licenses, permits and regulatory approvals; supply interruptions or labour disputes; foreign exchange fluctuations and collection risk; competition from other suppliers, or alternative, less capital intensive, energy solutions; and risk factors described elsewhere in this document under the heading "Risk Factors". We caution that the foregoing list of factors is not exhaustive, and that, when relying on forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider these factors, as well as other uncertainties and potential events, and the inherent uncertainty of forward-looking statements.

Although the Company has attempted to identify significant factors that could cause actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Forward-looking statements are provided as of the date of this MD&A, and the Company assumes no obligation to update or revise such forward-looking statements to reflect new events or circumstances except as required under applicable securities laws.

The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this MD&A are made as of the date of this MD&A or such other date specified herein.

## OVERVIEW

PyroGenesis Canada Inc. principal activities include the design, development, manufacturing and commercialization of advanced plasma processes. The Company provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working from its Montreal office and its 3,800m<sup>2</sup> production facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. PyroGenesis' core competencies allows the Company to be a leader in providing innovative plasma torches, plasma waste processes, plasma atomisation processes, high-temperature metallurgical processes, and engineering services to the global marketplace.



PyroGenesis' operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker symbol: PYR.V) and on the OTCQB in the United States (Ticker symbol: PYRNF).

## SELECTED FINANCIAL INFORMATION

	Three months ended Dec 31			% Change :016vs2015	Twelve months ended Dec 31			% Change 016vs2015
	2016	2015	2014		2016	2015	2014	
<b>Revenue</b>	\$ 1,483,543	\$ 2,228,782	\$ 1,784,676	-33%	\$ 5,222,133	\$ 6,242,003	\$ 5,764,896	-16%
Cost of sales and services other than undemoted write-offs	1,249,942	1,888,096	1,001,309	-34%	4,448,031	5,948,164	4,088,815	-25%
Gross profit before undemoted write-offs	233,600	340,686	783,367	-31%	774,102	293,839	1,676,081	163%
Write-off of inventories	994,015				994,015			
Write-off of costs and profits in excess of billings on uncompleted contracts	1,760,423				1,760,423			
Gross Profit (Loss)	(2,520,838)	340,686	783,367	-840%	(1,980,336)	293,839	1,676,081	-774%
<b>Expenses</b>								
Selling, general and administrative	968,523	1,227,999	1,421,869	-21%	4,320,862	4,648,473	4,530,083	-7%
Research and development	(14,692)	47,942	43,737	-131%	92,179	136,804	208,539	-33%
Finance income and finance costs	166,851	139,576	18,795	20%	558,842	426,341	216,069	31%
	1,120,682	1,415,517	1,484,401		4,971,883	5,211,618	4,954,691	
<b>Net loss and comprehensive loss</b>	\$ (3,641,520)	\$ (1,074,831)	(701,034)	239%	\$ (6,952,219)	\$ (4,917,779)	(3,278,610)	41%
Basic and diluted loss per share	\$ (0.04)	\$ (0.01)	(0.01)		\$ (0.07)	\$ (0.06)	(0.04)	
<b>Adjusted EBITDA (loss)</b>	\$ (505,875)	\$ (473,401)	(156,873)	7%	\$ (1,748,834)	\$ (2,602,987)	(1,181,533)	-33%

Adjusted EBITDA (loss) is not a performance measure defined under IFRS and it is not considered an alternative to Income (Loss) from operations or Comprehensive Earnings (Loss) in the context of measuring a Company's performance. Management believes that providing certain non-GAAP performance measures, in addition to IFRS measures, provides users of the Company's financial statements with an enhanced understanding of their results and related trends, and as such increases transparency and clarity. Adjusted EBITDA is an important measure of operating performance because it allows management, investors and others to evaluate and compare the Company's core operating results, including our return on capital and operating efficiencies, from period to period, by removing the impact of its capital structure (interest expense to service outstanding debt), asset base (depreciation and amortization), tax consequences, and other items not requiring cash outlays including share-based compensation, write-off of inventory and write off of costs and profits in excess of billings on uncompleted contracts. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. See "EBITDA and Adjusted ABITDA" for a reconciliation of these amounts.

### Extract from Statement of Financial Position at :

	Dec 31 2016	Dec 31, 2015	Dec 31, 2014
Current assets	1,968,963	3,343,186	3,439,490
Non-current assets	1,279,968	3,778,198	3,495,842
<b>Total assets</b>	<b>\$ 3,248,931</b>	<b>\$ 7,121,384</b>	<b>\$ 6,935,332</b>
Current liabilities	4,048,316	3,177,091	1,997,288
Non-current liabilities	3,605,897	3,328,722	2,059,792
<b>Total liabilities</b>	<b>\$ 7,654,213</b>	<b>\$ 6,505,813</b>	<b>\$ 4,057,080</b>
Shareholders' equity (deficiency)	\$ (4,405,282)	\$ 615,571	\$ 2,878,252

## RESULTS OF OPERATIONS

PyroGenesis recorded revenue of \$1,483,543 in the fourth quarter of 2016 ("Q4, 2016"), representing a decrease of 33% compared with \$2,228,782 recorded in the fourth quarter of 2015 ("Q4, 2015").

Total revenue recorded by the Company for 2016 amounted to \$5,222,133 and represents a decrease of 16% from the \$6,242,003 reported for 2015.



## Revenue

Revenues recorded in 2016 were generated primarily from:

- (i) the sale of intellectual property and development of a vacuum arc reducing process to convert Silica into high purity Silicon metal,
- (ii) the manufacture and further field testing of Tactical PACWADS, the first mobile plasma system for destruction of chemical warfare agents under contract with an international military consortium,
- (iii) separately, the demonstration of the viability of PyroGenesis' existing plasma chemical warfare agent destruction platform with locally available materials, for the complete eradication of chemical warfare agents without creating hazardous by-products,
- (iv) support services related to PAWDS-Marine systems supplied to the US Navy,
- (v) the manufacture and delivery of a fully automated plasma torch system comprised of six air plasma torches to be used for waste gasification. .

## Cost of Sales and Services and Gross Margin

### Cost of Sales and Services

	Three months ended Dec 31			Twelve months ended Dec 31		
	2016	2015	% Change 2016vs2015	2016	2015	% Change 2016vs2015
Employee compensation	\$ 386,549	\$ 541,679	-29%	\$ 1,765,997	\$ 1,928,009	-8%
Subcontracting	44,913	29,192	54%	173,190	294,331	-41%
Direct materials	380,719	1,119,681	-66%	741,800	2,238,443	-67%
Manufacturing overhead & other	172,965	201,796	-14%	596,826	648,227	-8%
Foreign exchange loss	14,088	61,382	-77%	23,093	(13,244)	-274%
Investment tax credits	(98,160)	(414,903)	-76%	(249,550)	(544,676)	-54%
<b>Sub-total before amortization of intangible assets</b>	<b>901,072</b>	<b>1,538,828</b>	<b>-41%</b>	<b>3,051,356</b>	<b>4,551,091</b>	<b>-33%</b>
Amortization of intangible assets	348,870	349,269	0%	1,396,675	1,397,074	0%
<b>Total Cost of Sales and Services</b>	<b>\$ 1,249,942</b>	<b>\$ 1,888,096</b>	<b>-34%</b>	<b>\$ 4,448,031</b>	<b>\$ 5,948,164</b>	<b>-25%</b>

### Gross Margin

	Three months ended Dec 31		Twelve months ended Dec 31	
	2016	2015	2016	2015
Revenue	\$ 1,483,543	\$ 2,228,782	\$ 5,222,133	\$ 6,242,003
Cost of sales and services before amortization of intangible assets and undemoted write-offs	901,068	1,538,828	3,051,356	4,551,091
Gross profit before amortization of intangible assets and undemoted write-offs	582,475	689,955	2,170,777	1,690,913
Gross margin before amortization of intangible assets and undemoted write-offs	39.3%	31.0%	41.6%	27.1%
Amortization of intangible assets	348,870	349,269	1,396,675	1,397,074
Gross profit before undemoted write-offs	\$ 233,605	\$ 340,686	\$ 774,102	\$ 293,839
Gross margin % before undemoted write-offs	15.7%	15.3%	14.8%	4.7%
Write-off of inventories	994,015	-	994,015	-
Write-off of costs and profits in excess of billings on uncompleted contracts	1,760,423	-	1,760,423	-
Gross Profit (Loss)	\$ (2,520,833)	\$ 340,686	\$ (1,980,336)	\$ 293,839
Gross Margin%	-169.9%	15.3%	-37.9%	4.7%

Gross margin before amortization of intangible assets and undemoted write-offs is not a performance measure defined under IFRS and it is not considered an alternative to gross margin in the context of measuring the Company's performance. Management believes that providing certain non-GAAP performance measures, in addition to IFRS measures, provides users of the Company's financial statements with an enhanced understanding of its results and related trends, and increases transparency and clarity. Gross margin before amortization of intangible assets and undemoted write-offs is an important measure of operating performance because it allows management, investors and others to evaluate and compare the Company's core operating results, including its return on capital and operating efficiencies, from period to period, by removing the impact of items not requiring cash outlays. Securities regulations require that companies caution readers



that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation.

Cost of sales and services before amortization of intangible assets was \$3,051,356 in 2016, representing a decrease of 33% compared with \$4,551,091 in 2015.

In 2016 employee compensation, subcontracting costs, direct materials and manufacturing overhead decreased to \$1,765,997 (2015-\$1,928,009), \$173,190 (2015-\$294,331), \$741,800 (2015-\$2,238,443), \$598,626 (2015-\$648,227) respectively. The cost of sales and services for 2016 are in line with management's expectations, whereas in 2015 cost of sales and services had increased primarily due to the work completed under PyroGenesis' project to design, manufacture and supply ten plasma-based powder production systems.

Investment tax credits recorded against cost of sales are primarily related to client funded projects that qualify for tax credits from the provincial government of Quebec. Qualifying tax credits decreased to \$ 249,550 in 2016, compared with \$544,676 in 2015. This represents a decrease of 54% year-over-year. The decrease is primarily due to a lower amount of these costs being eligible for tax credits following a review by the taxation authorities. The Company adjusted the 2016 qualifying tax credits to incorporate the results of a review of the 2015 tax credits by the tax authorities, where certain tax credits were disallowed in 2015.

The gross margin for 2016 before amortization of intangible assets and write-offs of inventories and costs and profits in excess of billings on uncompleted contracts was \$2,170,777, or 41.6% of revenue. This compares with a gross margin before amortization of intangible assets of \$1,690,913 (27.1% of revenue) for 2015. The inventory write-off is comprised of the TPWES system (\$147,774) and the CFC destruction system (846,241). The write-off of costs and profits in excess of billings on uncompleted contracts (\$1,760,423) was related to the Company no longer expecting to recover the full amounts owed from a customer for a contract.

The amortization of intangible assets of \$1,396,675 in 2016 and \$1,397,074 for 2015 relates to the licenses and know-how purchased in 2011 from a company under common control. Of note, this expense is a non-cash item and the underlying asset is fully amortized by December 31, 2016.

### ***Selling, General and Administrative Expenses***

	Three months ended Dec 31			Twelve months ended Dec 31		
	2016	2015	% Change 2016vs2015	2016	2015	% Change 2016vs2015
Employee compensation	\$ 558,708	\$ 640,225	-13%	\$ 2,165,025	\$ 2,133,623	1%
Professional fees	229,507	208,793	10%	922,892	1,127,745	-18%
Office and general	97,705	118,780	-18%	406,143	450,384	-10%
Travel	104,418	83,875	24%	204,246	255,110	-20%
Depreciation on property and equipment	31,584	41,123	-23%	127,405	163,727	-22%
Government grants	(3,375)	(10,000)	-66%	(31,832)	(54,224)	-41%
Other expenses	22,360	71,555	-69%	160,958	242,658	-34%
<b>Sub-total before Share-based payments</b>	<b>1,040,906</b>	<b>1,154,351</b>	<b>-10%</b>	<b>3,954,837</b>	<b>4,319,024</b>	<b>-8%</b>
Share-based payments	(166,098)	71,462	-332%	366,025	327,650	12%
<b>Total selling, general and administrative</b>	<b>\$ 874,808</b>	<b>\$ 1,225,813</b>	<b>-29%</b>	<b>\$ 4,320,862</b>	<b>\$ 4,646,674</b>	<b>-7%</b>

Included within Selling, General and Administrative expenses ("SG&A") are costs associated with corporate administration, business development, project proposals, operations administration, investor relations and employee training.

SG&A expenses for 2016 excluding the costs associated with share-based compensation (a non-cash item in which options vest over a four year period), were \$3,954,837, representing a decrease of 8% compared with \$4,319,024 reported for 2015.



The decrease in SG&A expenses in 2016 over the same period in 2015 is attributable to the net effect of:

- an increase of 1% in employee compensation,
- a decrease of 10% in office and general expenses primarily due to lower communication expenses,
- a decrease of 18% for professional fees primarily due to lower accounting fees,
- travel costs decreased by 20% primarily due to less travel abroad,
- depreciation on property and equipment decreased by 22% due to a reduced level of investment in machinery and equipment since 2010, when major acquisitions were made,
- government grants decreased by 41% due to lower level of activities supported by such grants and
- other expenses decreased by 34%, primarily due to the reduced cost of freight and shipping.

Separately, share based payments increased in 2016 over the same period in 2015 as a result of the vesting structure of the stock option plan and the stock options offered on September 25, 2016. On a year-to-date basis, share-based payments expense (a non-cash item) increased by 12%.

### **Research and Development (“R&D”) Costs**

	Three months ended Dec 31		% Change	Twelve months ended Dec 31		% Change
	2016	2015	2016vs2015	2016	2015	2016vs2015
Employee compensation	\$ (10,256)	\$ 32,726	-131%	\$ 73,591	\$ 134,983	-45%
Subcontracting	720	11,043	-93%	720	13,243	-95%
Materials and equipment	(4,392)	13,394	-133%	16,646	33,327	-50%
Other expenses	(764)	617	-224%	1,222	2,533	-52%
<b>Sub-total before government grants</b>	<b>(14,693)</b>	<b>57,780</b>	<b>-125%</b>	<b>92,179</b>	<b>184,087</b>	<b>-50%</b>
Government grants	-	(9,838)	-100%	-	(47,283)	-100%
<b>Total net R&amp;D costs</b>	<b>\$ (14,693)</b>	<b>\$ 47,942</b>	<b>-131%</b>	<b>\$ 92,179</b>	<b>\$ 136,804</b>	<b>-33%</b>

The Company incurred \$92,179 of R&D costs, net of government grants, on internal projects in 2016, a decrease of 33% as compared with \$136,804 in 2015. The decrease in 2016 is primarily due to capitalizing development expenditures relating to the asset under development in the amount of \$456,104.

In addition to internally funded R&D projects, the Company also incurred R&D expenditures during the execution of client funded projects. These expenses are eligible for Scientific Research and Experimental Development (“SR&ED”) tax credits. SR&ED tax credits on client funded projects are applied against cost of sales and services (see “Cost of Sales” above).

### **Finance Income and Finance Costs**

	Three months ended Dec 31		% Change	Twelve months ended Dec 31		% Change
	2016	2015	2016vs2015	2016	2015	2016vs2015
Finance income	\$ \$ (93,714)	\$ -	100%	\$ 80,700	\$ -	100%
Finance expenses	\$ 166,851	\$ 139,576	20%	\$ 639,542	\$ 426,341	50%
Net finance expenses	\$ 260,565	\$ 139,576	87%	\$ 558,842	\$ 426,341	31%

Finance income in 2016 resulted from a gain realized on the disposal of an investment in an amount of \$55,160 in Q1, 2016 and the adjustment to the fair market value of other investments in the amount of \$25,540 in Fiscal 2016.



Finance costs for 2016 totaled \$639,542 as compared with \$426,341 for 2015, representing an increase of 50% year-over-year. The increase in finance costs in 2016, is attributable to interest expenses on tax credit loans and an increase in accretion costs on convertible debentures, there were no tax credit loans in 2015.

### ***Depreciation on Property and Equipment***

	Three months ended Dec 31			Twelve months ended Dec 31		
	2016	2015	% Change 2016vs2015	2016	2015	% Change 2016vs2015
Depreciation on property and equipment	\$ 31,584	\$ 41,123	-23%	\$ 127,405	\$ 163,727	-22%

The depreciation on property and equipment decreased to \$127,405 in Fiscal 2016, compared with \$163,727 in Fiscal 2015. The 22% decrease reflects a reduced level of investments in machinery and equipment since 2010, when major acquisitions were made.

### ***Net loss and comprehensive loss***

	Three months ended Dec 31			Twelve months ended Dec 31		
	2016	2015	% Change 2016vs2015	2016	2015	% Change 2016vs2015
Comprehensive loss	\$ (3,641,515)	\$ (1,074,831)	239%	\$ (6,952,219)	\$ (4,917,779)	41%

The net comprehensive loss for 2016 of \$6,952,219 compared to a loss of \$4,917,779, in 2015, represents an increase in loss of 41% year-over-year. The net comprehensive loss includes a write-off amount of \$ 2,754,438. Year-to-date, loss from operations was \$4,197,781 as compared to comparable loss of \$4,917,779 for the same period in 2015, a decrease of 15%. The net loss from operations includes finance income in the amount of \$80,700 for 2016.

The net comprehensive loss for 2016 of \$6,952,219 compared to a loss of \$4,917,779, in 2015, represents an increase in loss of 41% year-over-year.

The increase of \$2,034,440 in the comprehensive loss in 2016 is primarily attributable to the factors described above, which have been summarized as follows:

- (i) a decrease in product and service related revenue of \$1,019,871 arising in 2016.
- (ii) a decrease in cost of sales and services totaling \$1,500,134, primarily due to the concentration of engineering on developing the 3D printing powder production system, and due to the decrease in product and service revenue.
- (iii) a decrease in SG&A expenses of \$327,611 arising in Fiscal 2016 primarily due to a decrease in professional fees,
- (iv) a decrease in R&D expenses of \$44,625 primarily due to the fact that some of the R&D expenses were capitalized.
- (v) an increase in net finance costs of \$132,501 that is primarily due to interest on the convertible debenture and the tax credit loans obtained in 2016
- (vi) an increase of \$2,754,438 for the write-off of inventories and costs and profits in excess of billings on uncompleted contracts.



## EBITDA and Adjusted EBITDA

	Three months ended Dec 31			Twelve months ended Dec 31		
	2016	2015	% Change 2016vs2015	2016	2015	% Change 2016vs2015
Comprehensive loss	\$ (3,641,515)	\$ (1,074,831)	239%	\$ (6,952,219)	\$ (4,917,779)	41%
Depreciation on property and equipment	31,584	41,123		127,405	163,727	
Amortization of intangible assets	348,870	349,269		1,396,675	1,397,074	
Financing charges	166,851	\$ 139,576		558,842	\$ 426,341	
<b>EBITDA (loss)</b>	<b>\$ (3,094,210)</b>	<b>\$ (544,863)</b>	<b>468%</b>	<b>\$ (4,869,297)</b>	<b>\$ (2,930,637)</b>	<b>66%</b>
Other non-cash items:						
Share-based payments	(166,098)	71,462		366,025	327,650	
Write-off of inventories	994,015			994,015		
Write-off of costs and profits in excess of billings on uncompleted contracts	1,760,423			1,760,423		
<b>Adjusted EBITDA (loss)</b>	<b>\$ (505,870)</b>	<b>\$ (473,401)</b>	<b>7%</b>	<b>\$ (1,748,834)</b>	<b>\$ (2,602,987)</b>	<b>-33%</b>

EBITDA is defined as Earnings (from operations) before Net Financing Charges, Taxes, Depreciation and Amortization and Adjusted EBITDA is defined as Earnings (from operations) before Net Financing Charges, Taxes, Depreciation, Amortization and other non-cash items including share-based payment costs, write-off of inventory and write off of costs and profits in excess of billings on uncompleted contracts.

EBITDA and Adjusted EBITDA are not performance measures defined under IFRS and they are not considered an alternative to income or loss from operations, or to comprehensive earnings or loss, in the context of measuring a company's performance. Management believes that providing certain non-GAAP performance measures, in addition to IFRS measures, provides users of the Company's financial statements with an enhanced understanding of its results and related trends and increases transparency and clarity. Management believes that EBITDA and Adjusted EBITDA are important measures of operating performance because it allows management, investors and others to evaluate and compare the Company's operating results, including its return on capital and operating efficiencies, from period-to-period by removing the impact of the Company's capital structure (interest expense to service outstanding debt), asset base (depreciation and amortization), tax consequences, and other items not requiring cash outlays including share-based compensation, write-off of inventory and write off of costs and profits in excess of billings on uncompleted contracts. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation.

The EBITDA loss in 2016 was \$4,869,297 compared with an EBITDA loss of \$2,930,637 for 2015, representing an increase of 66%. The increase in the EBITDA loss in 2016 compared with 2015 includes amounts written-off of \$2,754,438.

Adjusted EBITDA loss in 2016 was \$1,748,834 compared with an Adjusted EBITDA loss of \$2,602,987 for 2015. The decrease of \$854,153 in the Adjusted EBITDA loss in 2016 is attributable to the increased comprehensive loss of \$2,034,440, a decrease of \$36,322 in depreciation on property and equipment, a decrease of \$399 in amortization of intangible assets, an increase in finance charges of \$132,501, an increase in cost of other non-cash items, specifically share-based payments of \$38,375 an increase in write-off of inventories of \$994,015 and an increase in write-off of costs and profits in excess of billings on uncompleted contracts of \$1,760,423.

## SUMMARY OF QUARTERLY RESULTS

	2016				2015			
	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Revenues	\$ 1,483,543	\$ 1,902,748	\$ 818,990	\$ 1,016,853	\$ 2,228,782	\$ 1,363,077	\$ 1,533,667	\$ 1,116,477
Gross margin before amortization of intangible assets	582,475	1,220,643	74,063	293,597	689,975	373,715	325,089	302,154
gross margin %	39.3%	64.2%	9.0%	28.9%	31.0%	27.4%	21.2%	27.1%
Loss from operations	(887,077)	(717,041)	(1,345,000)	(1,298,663)	(1,074,831)	(1,267,748)	(1,296,111)	(1,279,089)
Comprehensive loss	(3,641,515)	(717,041)	(1,345,000)	(1,248,663)	(1,074,831)	(1,267,748)	(1,296,111)	(1,279,089)
Net loss per share - basic and diluted	(0.04)	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)	(0.02)



The majority of PyroGenesis' revenue is recognised using the percentage of completion basis, and is dependent on the timing of project initiation and execution, including project engineering, manufacturing, and testing.

## LIQUIDITY AND CAPITAL RESOURCES

The following table summarizes the contractual maturities of financial liabilities as at December 31, 2016.

	Total contractual cashflows	6 months or less	6 to 12 months	1-2 years
	\$	\$	\$	\$
Accounts payable and accrued liabilities	1,446,728	1,446,728	-	-
Loans	661,633	-	661,633	-
Convertible debentures	4,375,000	150,000	150,000	4,075,000
	6,483,361	1,596,728	811,633	4,075,000

The Company has incurred, in the last several years, operating losses and negative cash flows from operations, resulting in an accumulated deficit of \$37,026,405 as at December 31, 2016. Furthermore, as at December 31, 2016, the Company's current liabilities and expected level of expenses for the next twelve months exceed cash on hand of \$385,257. The Company has relied upon external financings to fund its operations in the past, primarily through the issuance of equity, debt, and convertible debentures, as well as from investment tax credits.

As at December 31, 2016 the Company has a strong backlog from signed contracts totaling 9.9MM, and a pipeline of prospective new projects resulting in the Company's business plan becoming less dependent on raising additional funds to finance operations within and beyond the next 12 months. While the Company has been successful in securing financing in the past, raising additional funds is dependent on a number of factors outside the Company's control, and as such there is no assurance that it will be able to do so, should it need to, in the future. If the Company is unable to obtain sufficient additional financing when needed, it may have to curtail operations and development activities, any of which could harm the business, financial condition and results of operations. Until such financing is secured, there exists a material uncertainty that may cast significant doubt about the Company's ability to continue operating as a going concern and realize its assets and settle its liabilities and commitments in the normal course of business. See note 1(b) to the financial statements.

On July 26, 2016, the Company completed the following transactions:

- Share for debt transaction to settle outstanding debt whereby the Company issued 2,060,126 common shares of the Company from treasury at a deemed price of \$0.20 per common share in the aggregate amount of \$412,025.
- Private placement whereby the Company issued and sold an aggregate amount of 6,131,579 units of the Company at a price of \$0.19 per unit, for a gross proceeds of \$1,165,000.

As at December 31, 2016, the Company had cash on hand of \$385,257 and negative working capital of \$2,079,353 compared with a cash balance of \$767,368 and positive working capital of \$166,095 as at December 31, 2015.

Revenue generated from active projects does not yet produce sufficient positive cash flow to fund operations. However, based on current backlog of \$9.9MM at April 28, 2017 (over 47% of 2016 revenues), together with the pipeline of prospective new projects, cash flow from operations are expected to become positive in the near term.



## OFF-BALANCE SHEET ARRANGEMENTS

The Company had no off-balance sheet arrangements as at December 31, 2016, other than lease commitments for premises and automobiles as discussed in note 23 to the financial statements.

## SUMMARY OF CASH FLOWS

	Three months ended Dec 31		Twelve months ended Dec 31	
	2016	2015	2016	2015
Cash provided by (used in) operating activities	\$ 741,629	\$ (1,252,764)	\$ (1,372,907)	\$ (3,441,924)
Cash provided by (used in) investing activities	(152,520)	50,000	(401,020)	(32,935)
Cash provided by (used in) financing activities	(410,005)	1,701,428	1,391,816	3,880,044
Increase (decrease) in cash	179,104	498,664	(382,111)	405,185
Cash - beginning of period	206,153	268,704	767,368	362,183
Cash - end of period	385,257	767,368	385,257	767,368

For the three months ended December 31, 2016, cash flow from operating activities generated cash of \$741,629 compared to a net use of \$1,252,764 for the same period in the prior year.

The use of cash during 2016 consists of the comprehensive loss of \$6,952,219 (2015: \$4,917,779) plus adjustment for non-cash items totalling \$5,167,385 (2015: \$2,314,792) less a net change in non-cash operating working capital items of \$774,294 (2015: negative net change in non-cash operating working capital items of \$475,712) plus interest paid of \$362,367 (2015: interest paid of \$363,225).

The net change in non-cash operating working capital items was driven by:

- an increase in accounts receivable of \$3,531 in 2016, compared to a decrease of \$994,362 in 2015;
- a decrease in sales tax receivable of \$222,151 in 2016, compared to an increase of \$123,881 in 2015;
- an increase in costs and profits in excess of billings on uncompleted contracts of \$403,330 in 2016, compared to an increase of \$898,883 in 2015;
- a change in inventory of \$Nil in 2016, compared to an increase of \$846,241 in 2015;
- a decrease in investment tax credits receivable of \$209,526 in 2016, compared to an increase of \$356,153 in 2015;
- a decrease in prepaid expenses of \$64,828 in 2016, compared to an increase of \$27,937 in 2015;
- a decrease in accounts payable and accrued liabilities of \$348,128 in 2016, compared to an increase of \$909,628 in 2015;
- an increase in billings in excess of costs and profits on uncompleted contracts of \$1,032,778 in 2016, compared with a decrease of \$76,608 in 2015.

Investing activities resulted in a use of cash of \$401,020 in 2016, compared to a use of cash of \$32,935 in 2015 resulting from the net variation of investments in 2016 and purchase of property and equipment in 2015.

Financing activities in 2016 resulted in a net source of funds of \$1,391,816, compared with a net source of funds of \$3,880,044 in 2015. In 2016, the Company completed loans and a private placement through which net cash proceeds of \$1,037,000 and \$1,093,216 respectively, were



raised for general working capital purposes and issued common shares for debt transactions in the amount of \$412,025.

For 2016, the net cash position of the Company decreased by \$382,111, compared to a net increase of \$405,185 for the same period in the prior year.

### CAPITAL STOCK INFORMATION

The authorized share capital of the Company consists of an unlimited number of Class A common shares (the "Common Shares"). As at April 28, 2017, PyroGenesis had 104,501,291 Class A Common Shares, 7,070,790 warrants, 9,751,000 outstanding options issued and 7,748,000 exercisable options issued.

### GOING CONCERN

*Cash generated from contracts and from providing engineering services to clients has historically been insufficient to meet the overall cash requirements of the Company to cover operating costs. For the Company to generate sufficient positive cash flows from operations and meet current cash requirements, the level of business must exceed that recorded to date. Management expects that the investments currently being made in accelerating projects under development for various clients, together with executing on the \$9.9MM backlog at April 28, 2017, (over 90% of 2016 revenues) which is primarily related to the Company's successful diversification into niche markets of the additive manufacturing (including 3D printing), and metals & mining industries, will continue to improve the Company's cash position.*

To date, the Company has raised financing primarily through successive issuances of equity and convertible debentures. There is no certainty that the Company will continue to be able to raise additional financing or expand its sales to fund its operations, although management is confident that it will be able to do so. These conditions indicate the existence of a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern.

The December 31, 2016 financial statements have been prepared using International Financial Reporting Standards ("IFRS"), which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due. If the going concern assumption were not appropriate for these financial statements then adjustments would be necessary to the carrying value of assets and liabilities, the reported expenses and the statements of financial position classifications used. The impact on the financial statements could be material.

### RELATED PARTY TRANSACTIONS

Rent was charged by a trust beneficially owned by a shareholder of the Company in the amount of \$188,781 (2015 - \$181,980). A balance due of \$40,688 (2015 - \$72,279) is included in accounts payable and accrued liabilities.

Interest on balance of sale was charged by a company under common control in the amount of \$Nil (2015 - \$12,841). The balance of interest that has not been paid of \$317,319 (2015 - \$317,319) is included in loans.

Interest on the convertible debentures was charged by a shareholder of the Company in the amount of \$56,640 (2015 - \$42,516).

Fees of \$46,000 were charged for services rendered by the independent directors who are members of the Company's Board of Directors (2015 - \$47,000).

Fees of \$Nil were charged for professional services rendered by a company controlled by a director of the Company (2015 - \$116,000).



As part of the private placement of December 11, 2015 (see note 16 (ii)), 6,800,000 units were issued at a price of \$0.20 each for a gross proceeds of \$1,360,000 to shareholders and key management of the Company.

As part of the unsecured and subordinated convertible debentures of \$4,000,000 issued March 30, 2015, 1,000,000 convertible debentures were issued at a price of \$0.80 each as settlement of \$755,000 of the Balance of Sale due to a shareholder of the Company.

As part of a stock option incentive plan, on September 25, 2016, 4,350,000 common shares at a price of \$0.18 in the capital of the company were granted to the Directors of the Company. The options will be exercisable for a period of five (5) years commencing on the date of the grant. During the year ended December 31, 2016, the total compensation to key management amounted to \$654,939 (2015 - \$670,533).

### SUBSEQUENT EVENTS

Subsequent to December 31, 2016, in February and March 2017 PyroGenesis received the 3<sup>rd</sup> and 4<sup>th</sup> progress payments, totaling \$1,062,000, under a previously announced \$8.3MM contract with HPQ Silicon Resources Inc. to provide a 200 metric tonne(MT) per year PUREVAP™ pilot system capable of producing silicon metal directly from quartz.

In March 2017, PyroGenesis completed the assembly of its first powder production system and underwent a successful first powder run, which exceeded expectations both in terms of powder quality and production rate.

In April 2017, PyroGenesis has, in coordination with the US-based Southwest Research Institute (SwRI), successfully completed long-duration performance tests using the Company's tactical Plasma Arc Chemical Warfare Agents Destruction System using surrogate chemical warfare agent material. These tests supported the Defense Advanced Research Projects Agency (DARPA) Agnostic Compact Demilitarization of Chemical Agents (ACDC) program and far exceeded minimum requirements with over 99.9999% destruction efficiency.

From January to March 2017, PyroGenesis received an aggregate amount of \$417,857 from the exercise of a series of warrants which were previously issued by the Company in connection with a private placement offering completed on November 26, 2014. As a result of such exercise, the Company issued 2,142,857 Common Shares in its share capital.

### CRITICAL ACCOUNTING ESTIMATES, NEW AND FUTURE ACCOUNTING POLICIES AND FINANCIAL INSTRUMENTS

For a discussion of critical accounting estimates, new and future accounting policies and financial instruments, please refer to notes 4, 5 and 19 of the 2016 Financial Statements.

### RISK FACTORS

PyroGenesis is subject to a number of risks and uncertainties that could significantly affect the Company's financial condition and performance. This list of risk factors may not be exhaustive as the Company operates in a rapidly changing business environment and new risk factors emerge from time to time. The Company cannot predict such risk factors, nor can the Company assess the impact, if any, of such risk factors or uncertainties on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those projected in any forward-looking statements. Accordingly, neither shareholders of the Company nor purchasers of securities of the Company should rely on forward-looking statements as a prediction of actual results. If any of these risks actually occur, the Company's business, results of operations, financial position and cash flows could be adversely affected. In any such case, the market price of the Company's common shares could decline and investors may lose all or part of their investment.



### **Revenue Risks**

PyroGenesis may experience delays in achieving revenues, particularly with plasma gasification projects which have a long sales cycle. Revenues may be delayed or negatively impacted by issues encountered by the Company or its clients including:

- (a) unforeseen engineering and/or environmental problems;
- (b) delays or inability to obtain required financing, licenses, permits and/or regulatory approvals;
- (c) supply interruptions and/or labour disputes;
- (d) foreign exchange fluctuations and/or collection risk; and
- (e) competition from other suppliers and/or alternative energy solutions that are less capital intensive.

There is no assurance that the business will perform as expected or that returns from the business will support the expenditures needed to develop it.

In addition, as previously explained, the Company has experienced and has been dealing with technical issues under an existing contract with a customer based in Asia since December 31, 2015. At the date of this MD&A, these differences have not yet been resolved and the timing of the resolution remains uncertain. Management believes that the Company has respected the terms of the contract; however based on discussions with the customer during the year, the Company no longer expects to recover the full amounts owing under the contract from the customer. Accordingly, we wrote-off an amount of \$1,760,423 related to this contract during the year.

### **Technology Development and Manufacturing Capability Risks**

PyroGenesis recently expanded into new areas of business and, as a result, many of the Company's products are at various stages of the development cycle. The Company may be unable to commercialise such products or it may be unable to manufacture such products in a commercially viable manner. Whilst management is confident in both its technology and in its team of experienced engineers, scientists and technicians, it cannot know with certainty, which of its products will be commercialised, when such products will be commercialised, or whether such products will be able to be manufactured and distributed profitably.

### **Lack of Product Revenues/History of Losses**

PyroGenesis has incurred losses in the majority of years since its inception. The Company's operations have not generated sufficient earnings and cash flows to date to result in consistent profitability or positive cash flow. Consequently, the Company's continued existence is dependent upon its ability to generate profitable operations by establishing and expanding its client base and/or raising adequate long term financing. PyroGenesis has relied primarily on equity financing, debt financing, partner funding and government funding to carry on its business to date. The ability of the Company to achieve profitable sustainable operations in the future is uncertain. PyroGenesis has not yet demonstrated its ability to consistently achieve positive gross margins and its ongoing efforts to improve product gross margins may be insufficient to result in profitability.

### **Additional financing and dilution**

PyroGenesis will require additional financing to support ongoing operations and to undertake capital expenditures. There can be no assurance that additional financing will be available to the Company when needed, or on terms acceptable to the Company. PyroGenesis' inability to raise financing to support ongoing operations or to fund capital expenditures could limit the Company's growth and may have a material adverse effect upon the Company.



The Company does not exclude raising additional funds by equity financing. In addition, at April 28, 2017, 9,751,000 stock options are currently issued and outstanding, together with 7,320,790 warrants and 5,000,000 convertible debentures. The exercise of stock options and/or warrants, together with the conversion of debentures, as well as any new equity financings, represents dilution factors for present and future shareholders.

### ***Sales Cycle and Fixed Price Contracts***

PyroGenesis sales cycle is long and the signing of new contracts is subject to delay, over which the Company has little control. The Company also enters into sales contracts with fixed pricing, which may be impacted by changes over the period of implementation. There is no assurance that delays or problems in fulfilling contracts with clients will not adversely affect the Company's activities, operating results or financial position.

### ***Reliance on Technology***

PyroGenesis will depend upon continuous improvements in technology to meet client demands in respect of performance and cost, and to explore additional business opportunities. There can be no assurance that the Company will be successful in its efforts in this regard or that it will have the resources available to meet this demand. Whilst management anticipates that the research and development will allow the Company to explore additional business opportunities, there is no guarantee that such business opportunities will be presented or realised. The commercial advantage of the Company will depend to a significant extent on the intellectual property and proprietary technology of PyroGenesis and the ability of the Company to prevent others from copying such proprietary technologies. PyroGenesis currently relies on intellectual property rights and other contractual or proprietary rights, including (without limitation) copyright, trade secrets, confidential procedures, contractual provisions, licenses and patents, to protect its proprietary technology. PyroGenesis may have to engage in litigation in order to protect its patents or other intellectual property rights, or to determine the validity or scope of the proprietary rights of others. This type of litigation can be expensive and time consuming, regardless of whether or not the Company is successful. PyroGenesis may seek patents or other similar protections in respect of particular technology; however, there can be no assurance that any future patent applications will actually result in issued patents, or that, even if patents are issued, they will be of sufficient scope or strength to provide meaningful protection or any commercial advantage to the Company. Moreover, the process of seeking patent protection can itself be long and expensive. In the meantime, competitors may develop technologies that are similar or superior to PyroGenesis' technology or design around the patents owned by the Company, thereby adversely affecting the Company's competitive advantage in one or more of its areas of business. Despite the efforts of the Company, its intellectual property rights may be invalidated, circumvented, challenged, infringed or required to be licensed to others. It cannot be assured that any steps the Company may take to protect its intellectual property rights and other rights to such proprietary technologies that are central to the Company's operations will prevent misappropriation or infringement of its technology.

### ***Changes to Contracts***

PyroGenesis is dependent upon its ability to establish and develop new relationships and to build on existing relationships with current clients. The Company cannot provide assurance that it will be successful in maintaining or advancing its relationships with current clients or procure additional clients. In addition, PyroGenesis cannot provide assurance that the U.S. Military and/or other military clients will continue to provide the Company with business. Sales to governments and governmental entities are subject to specific additional risks, such as delays in funding, termination of contracts or sub-contracts at the convenience of the government, termination, reduction or modification of contracts or sub-contracts in the event of changes in the government's policies or as a result of budgetary constraints, and increased or unexpected costs resulting in losses or reduced profits under fixed price contracts.



### ***Foreign Exchange Exposure***

PyroGenesis' products and services are increasingly being sold in markets outside of Canada, whilst most of its operating expenses and capital expenditures are denominated in Canadian dollars. As a result, the Company is exposed to fluctuations in the foreign exchange rates between Canadian dollar and the currency in which a particular sale is transacted, which may result in foreign exchange losses that could affect earnings.

### ***Competition***

The industry is competitive and PyroGenesis competes with a substantial number of companies which have greater technical and financial resources. There can be no assurance that such competitors will not substantially increase the resources devoted to the development and marketing of products and services that compete with those of the Company or that new or existing competitors will not enter the various markets in which PyroGenesis is active. There can be no assurance that competitors will not develop new and unknown technologies with which the Company may have difficulty competing. Furthermore, failure to remain cost competitive may result in PyroGenesis losing business to its competitors.

### ***Management and Key Personnel***

PyroGenesis depends on the skills and experience of its management team and other key employees. The Company relies heavily on its ability to attract and retain highly-skilled personnel in a competitive environment. PyroGenesis may be unable to recruit, retain, and motivate highly-skilled employees in order to assist the Company's business, especially activities that are essential to the success of the Company. Failure to recruit and retain highly-skilled employees may adversely affect PyroGenesis' business, financial condition and results of operations.

### ***Implementation of a strategic plan***

PyroGenesis' commercial strategy aims to leverage its products, consumables, and services whilst focusing on the resolution of problems within niche markets within the industries served by the Company. There can be no assurances as to the success of the Company's strategic plan, which should be considered under the risks perspective and difficulties frequently encountered by a developing business.

### ***Adverse Decisions of Sovereign Governments***

PyroGenesis conducts an increasing portion of its business internationally. There is no assurance that any sovereign government, including Canada's, will not establish laws or regulations that will not be detrimental to the Company's interests or that, as a foreign corporation, it will continue to have access to the regulatory agencies in other countries. Governments have, from time to time, established foreign exchange controls, which could have a material adverse effect on the Company's business, financial condition and results of operations.

### ***Governmental Regulation***

PyroGenesis is subject to a variety of federal, provincial, state, local and international laws and regulations relating namely to the environment, health and safety, export controls, currency exchange, labour and employment and taxation. These laws and regulations are complex, change frequently and have tended to become more stringent over time. Failure to comply with these laws and regulations may result in a variety of administrative, civil and criminal enforcement measures, including assessment of monetary penalties, imposition of remedial requirements and issuance of injunctions as to future compliance. The Company may be subject to compliance audits by regulatory authorities in the various countries in which it operates.



### ***Environmental Liability***

PyroGenesis is subject to various environmental laws and regulations enacted in the jurisdictions in which it operates, which govern the manufacturing, processing, importation, transportation, handling and disposal of certain materials used in the Company's operations. Management believes that it has adequate procedures in place to address compliance with current environmental laws and regulations. Furthermore, management monitors the Company's practices concerning the handling of environmentally hazardous materials. However, there can be no assurance that the Company's procedures will prevent environmental damage occurring from spills of materials handled by the Company or that such damage has not already occurred. On occasion, substantial liabilities to third parties may be incurred. The Company may have the benefit of insurance maintained by it or the operator, however, the Company may become liable for damages against which it cannot adequately insure or against which it may elect not to insure because of high costs or other reasons. The Company's clients are subject to similar environmental laws and regulations, as well as limits on emissions to the air and discharges into surface and sub-surface waters. While regulatory developments that may follow in subsequent years could have the effect of reducing industry activity, the Company cannot predict the nature of the restrictions that may be imposed. The Company may be required to increase operating expenses or capital expenditures in order to comply with any new restrictions or regulations.

### ***Product Liability and Other Lawsuits***

PyroGenesis is subject to a variety of potential product liabilities claims and other lawsuits related with its operations, including liabilities and expenses associated with product defects. The Company maintains product liability and other insurance coverage that management believes is generally in accordance with the market practice in its industry, but there can be no assurance that the Company will always be adequately insured against all such potential liabilities.

### ***Market Liquidity***

The market price for the common shares of the Company could be subject to wide fluctuations. Factors such as the announcement of significant contracts, technological innovations, new commercial products, patents, a change in regulations, quarterly financial results, future sales of common shares by the Company or current shareholders, and many other factors could have considerable repercussions on the price of the Company's common shares. In addition, the financial markets may experience significant price and value fluctuations that affect the market prices of equity securities of companies that sometimes are unrelated to the operating performance of these companies. Broad market fluctuations, as well as economic conditions generally may adversely affect the market price of the Company's common shares.

### ***Information systems disruptions***

The Company's business depends on the efficient and uninterrupted operation of its computer and communications software, hardware systems, and its other information technology. If such systems were to fail, or the Company was unable to successfully expand the capacity of these systems or integrate new technologies into its existing systems, its operations and financial results could be adversely affected.



## OUTLOOK

2016 has been a pivotal year for PyroGenesis as the Company shifted its focus away from being a fabricator of plasma-based systems that produced unique titanium powders, in favour of becoming a producer of such powders for the Additive Manufacturing Industry. These powders are greatly sought after by the Additive Manufacturing industry given their unique properties which include pure, small, spherical, and uniform, allowing them to flow like water; a characteristic that is extremely important in industries such as 3D printing.

This strategic decision, made in early 2016, combined with the termination of the \$12.5 MM contract to deliver 10 powder production systems to a client in Asia, put significant pressure on cash flows, which was further exacerbated by the need to secure funds to build our first production unit. We are happy to announce that we have been successful on both fronts.

Removing the effect of the onetime non-cash write-offs of \$2.8MM reveals the following results for 2016.

- Gross profit increased from 27% in 2015 to over 41% in 2016 despite a decrease in Revenues by 16% to \$5.2MM in 2016 over 2015;
- Adjusted EBITDA loss decreased from (\$2.6MM) in 2015 to (\$1.7MM) in 2016;
- Over \$13.5MM in contracts were signed, and work begun on, since June 30, 2016 which, taken in context of historic revenues (2016: \$5.2MM; 2015: \$6.2MM; 2014: \$5.8MM) is quite significant. A significant portion of these contracts are expected to run through the financials in 2017. None of these revenues reflect any contracts for the sale of powders.

As previously mentioned, 2017 looks like a breakout year for a number of reasons, including:

- The healthy gross margin (before consideration of the 2016 write-offs) established in 2016 is not only expected to continue into the foreseeable future, but improve once powder production is in full swing.
- Established backlog of signed contracts, the majority of which are expected to be completed in 2017.
- Our traditional lines of business are poised to contribute significantly to the bottom line, namely:

A) Powder Production: The Company has met every milestone announced on the road to making metal powders for the Additive Manufacturing (“AM”) Industry. It was recently announced that the assembly of the first powder production system was completed and that the first powder run exceeded expectations. The ramp up is under way and is expected to take place linearly over approximately four (4) months of which we are currently 25% complete. As announced in recent press releases interest has far exceeded Managements’ expectations and an initial contract was signed for a sample amount of powder. Also recently announced was the fact that the Company has signed a number of agreements with significant and potential players in the AM industry reflecting various discussions regarding the possibility of concluding certain business relationships or transactions geared to the production of powders. This bodes well for 2017. The current system is the first of many PyroGenesis expects to make to address an increasing need for metal powders in the AM industry.<sup>1</sup>

B) DROSRITE™: The DROSRITE™ Furnace System was proven out at a North American customer’s Mexican facility during the first half of 2016. Soon thereafter, a

---

<sup>1</sup> *Wohlers Report 2016 (ISBN 978-0-9913332-2-6)*



successful demonstration of the DROSRITE™ System in the Middle East took place, following which an unsolicited request to exclusively market the process in the region was received and is currently being discussed. Management's belief that the supply and installation of the first commercial sale in North America would enable the Company to leverage this success to generate a continued flow of orders for additional DROSRITE™ systems is being borne out. This recent flurry of activity and interest for the DROSRITE™ system bodes well for 2017 where we now expect to have at least 3 orders placed and delivered. We expect the first follow on contracts to be signed in the 2<sup>nd</sup> half of 2017. The market potential for PyroGenesis' DROSRITE™ system, from Aluminium dross alone, exceeds \$400MM.

C) HPQ: On August 2, 2016 PyroGenesis announced that it had signed contracts totalling CDN \$8,260,000 with HPQ Silicon Resources Inc., formally Uragold Bay Resources Inc. for the sale of IP and to provide a 200 metric tonne (MT) per year PUREVAP™ pilot system to produce silicon metal directly from quartz. This system will for the most part be constructed in 2017, with advancement of the contract accelerating in the second half of the year. According to percent completion accounting standards for revenue recognition the majority of these revenues will be recognized in the 2<sup>nd</sup> half of 2017. Of note, if successful, PyroGenesis benefits from a 10% royalty on all revenues derived from the use of this system by HPQ, subject to annual minimums.

D) Chemical Warfare Destruction System: The Company recently announced that PyroGenesis has, in coordination with the US-based Southwest Research Institute (SwRI), successfully completed long-duration performance tests using the Company's tactical Plasma Arc Chemical Warfare Agents Destruction System ("PACWADS") using surrogate chemical warfare agent material. These tests supported the Defense Advanced Research Projects Agency (DARPA) Agnostic Compact Demilitarization of Chemical Agents (ACDC) program and far exceeded minimum requirements with over 99.9999% destruction efficiency. The PACWADS is now scheduled to go through final testing using real chemical warfare agents by the US Military). These tests should be completed by the end of Q3 2017 (this timeline, however is out of the Company's control). Again this bodes well for 2017 as we would expect additional contracts resulting from a successful completion of the final testing. However, no indication has been given as to the size, if any, such procurement would entail.

E) Other Contracts: There are other contracts being discussed (such as a third order for a PAWDS for a New US Aircraft Carrier which is expected to be ordered sometime towards the end of 2017/beginning of 2018 with an estimated value of approximately \$6MM; SPARC system sales, amongst others) which give us confidence that overall 2017 looks like a break out year..

These points are strongly indicative of a strong performance in the coming year, and based on existing contracts, the Company expects to be profitable in 2017 excluding any contribution from powder sales as noted above. Further underscoring the sentiment for 2017 is how our entrance as a powder producer has been so well received by the Additive Manufacturing community.

Management remains focused on reducing PyroGenesis' dependency on long-cycle projects by developing a strategic portfolio of volume driven, high margin/low risk products that resolve specific problems within niche markets, and doing so by introducing these plasma-based technologies to industries that have yet to consider such solutions.

Management is also actively targeting recurring revenue opportunities that will generate a growing, and profitable, regular cash flow to the Company.

PyroGenesis has one of the largest concentrations of plasma expertise in the world, with over 250 years of accumulated technical experience and 59 patents, combined with unique



relationships with major Universities performing cutting edge plasma research and development, which positions the Company well to execute this strategy.

All indications are that 2017 will be a breakout year for more than one of the Company's product lines. The Company's focus will continue to be to generate an improved mix of short and long term projects that will, in turn, facilitate operational and financial planning. Repeat orders for the same, or similar, products will further result in the standardization of manufacturing processes which will lead to improved gross margins.

Additional information regarding the Company can be found on SEDAR at [www.sedar.com](http://www.sedar.com) OTC Markets ([www.otcmarkets.com](http://www.otcmarkets.com)) and on the Company's website at [www.pyrogenesis.com](http://www.pyrogenesis.com)